These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38964285)

  • 1. Effects of Simvastatin on Inflammatory Response and Biological Behaviour of Adamantinomatous Craniopharyngioma.
    Li W; Zhang Y; Zhuang Y; Chen R; Xiong Z; Li K; Liu F; Xu H; Li D; Peng J
    Neuroendocrinology; 2024; 114(10):934-949. PubMed ID: 38964285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin‑6 induces an epithelial‑mesenchymal transition phenotype in human adamantinomatous craniopharyngioma cells and promotes tumor cell migration.
    Zhou J; Zhang C; Pan J; Chen L; Qi ST
    Mol Med Rep; 2017 Jun; 15(6):4123-4131. PubMed ID: 28487953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug priming enhances radiosensitivity of adamantinomatous craniopharyngioma via downregulation of survivin.
    Stache C; Bils C; Fahlbusch R; Flitsch J; Buchfelder M; Stefanits H; Czech T; Gaipl U; Frey B; Buslei R; Hölsken A
    Neurosurg Focus; 2016 Dec; 41(6):E14. PubMed ID: 27903123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target.
    Apps JR; Carreno G; Gonzalez-Meljem JM; Haston S; Guiho R; Cooper JE; Manshaei S; Jani N; Hölsken A; Pettorini B; Beynon RJ; Simpson DM; Fraser HC; Hong Y; Hallang S; Stone TJ; Virasami A; Donson AM; Jones D; Aquilina K; Spoudeas H; Joshi AR; Grundy R; Storer LCD; Korbonits M; Hilton DA; Tossell K; Thavaraj S; Ungless MA; Gil J; Buslei R; Hankinson T; Hargrave D; Goding C; Andoniadou CL; Brogan P; Jacques TS; Williams HJ; Martinez-Barbera JP
    Acta Neuropathol; 2018 May; 135(5):757-777. PubMed ID: 29541918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential Expression of Stem Cell Markers in Human Adamantinomatous Craniopharyngioma and Pituitary Adenoma.
    Chang CV; Araujo RV; Cirqueira CS; Cani CM; Matushita H; Cescato VA; Fragoso MC; Bronstein MD; Zerbini MC; Mendonca BB; Carvalho LR
    Neuroendocrinology; 2017; 104(2):183-193. PubMed ID: 27161333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does the calcification of adamantinomatous craniopharyngioma resemble the calcium deposition of osteogenesis/odontogenesis?
    Song-Tao Q; Xiao-Rong Y; Jun P; Yong-Jian D; Jin L; Guang-Long H; Yun-Tao L; Jian R; Xiang-Zhao L; Jia-Ming X
    Histopathology; 2014 Feb; 64(3):336-47. PubMed ID: 24387671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD47 promotes the proliferation and migration of adamantinomatous craniopharyngioma cells by activating the MAPK/ERK pathway, and CD47 blockade facilitates microglia-mediated phagocytosis.
    Zhang H; Wang C; Fan J; Zhu Q; Feng Y; Pan J; Peng J; Shi J; Qi S; Liu Y
    Neuropathol Appl Neurobiol; 2022 Jun; 48(4):e12795. PubMed ID: 35156226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent adamantinomatous craniopharyngiomas show MAPK pathway activation, clonal evolution and rare TP53-loss-mediated malignant progression.
    Apps JR; Gonzalez-Meljem JM; Guiho R; Pickles JC; Prince E; Schwalbe E; Joshi N; Stone TJ; Ogunbiyi O; Chalker J; Bassey A; Otto G; Davies R; Hughes D; Brandner S; Tan E; Lee V; Hayhurst C; Kline C; Castellano S; Hankinson T; Deutschbein T; Jacques TS; Martinez-Barbera JP
    Acta Neuropathol Commun; 2024 Aug; 12(1):127. PubMed ID: 39127699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative immunohistochemical expression of β-catenin, EGFR, ErbB2, and p63 in adamantinomatous and papillary craniopharyngiomas.
    Esheba GE; Hassan AA
    J Egypt Natl Canc Inst; 2015 Sep; 27(3):139-45. PubMed ID: 26198262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma.
    Coy S; Rashid R; Lin JR; Du Z; Donson AM; Hankinson TC; Foreman NK; Manley PE; Kieran MW; Reardon DA; Sorger PK; Santagata S
    Neuro Oncol; 2018 Jul; 20(8):1101-1112. PubMed ID: 29509940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calretinin is expressed in the stroma of adamantinomatous craniopharyngioma and may induce calcification.
    Chaohu W; Yi L; Hai H; Hui Z; Jun P; Song-Tao Q
    Clin Neurol Neurosurg; 2015 Nov; 138():124-8. PubMed ID: 26319618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteoblastic differentiation and cell calcification of adamantinomatous craniopharyngioma induced by bone morphogenetic protein-2.
    Yan X; Kang D; Pan J; Jiang C; Lin Y; Qi S
    Cancer Biomark; 2017; 18(2):191-198. PubMed ID: 27983534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Axl as a potential therapeutic target for adamantinomatous craniopharyngiomas: Based on single nucleus RNA-seq and spatial transcriptome profiling.
    Chen Y; Liu X; Ainiwan Y; Li M; Pan J; Chen Y; Xiao Z; Wang Z; Xiao X; Tang J; Zeng G; Liang J; Su X; Kungulli R; Fan Y; Lin Q; Liya A; Zheng Y; Chen Z; Xu C; Zhang H; Chen G
    Cancer Lett; 2024 Jun; 592():216905. PubMed ID: 38677641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible linkage between specific histological structures and aberrant reactivation of the Wnt pathway in adamantinomatous craniopharyngioma.
    Kato K; Nakatani Y; Kanno H; Inayama Y; Ijiri R; Nagahara N; Miyake T; Tanaka M; Ito Y; Aida N; Tachibana K; Sekido K; Tanaka Y
    J Pathol; 2004 Jul; 203(3):814-21. PubMed ID: 15221941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of simvastatin on proliferation and apoptosis of acute monocytic leukemia cell line SHI-1].
    Li YF; Zhang R; Zhang XH; Chen GH; Cen JN; Zhu ZL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Jun; 19(3):612-6. PubMed ID: 21729534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and inhibition of ADAMDEC1 in craniopharyngioma cells.
    Xu J; Liu L; Zheng X; You C; Li Q
    Neurol Res; 2012 Sep; 34(7):701-6. PubMed ID: 22776555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical expression of ErbB2 in adamantinomatous craniopharyngiomas: a possible target for immunotherapy.
    Zuhur SS; Tanik C; Erol RS; Musluman AM; Kabukcuoglu F; Altuntas Y
    Turk Neurosurg; 2013; 23(1):55-60. PubMed ID: 23344868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and prognostic role of annexin A2 in adamantinomatous craniopharyngioma.
    Wang Y; Deng J; Guo G; Tong A; Peng X; Chen H; Xu J; Liu Y; You C; Zhou L
    J Neurooncol; 2017 Jan; 131(1):21-29. PubMed ID: 27640198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CXCL12/CXCR4 promotes proliferation, migration, and invasion of adamantinomatous craniopharyngiomas via PI3K/AKT signal pathway.
    Yin X; Liu Z; Zhu P; Wang Y; Ren Q; Chen H; Xu J
    J Cell Biochem; 2019 Jun; 120(6):9724-9736. PubMed ID: 30582214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological Behaviour of Craniopharyngiomas.
    Martinez-Barbera JP; Andoniadou CL
    Neuroendocrinology; 2020; 110(9-10):797-804. PubMed ID: 32126562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.